Refining therapeutic targeting of interleukin-6 by signalling mode selectivity.

Selective targeting of IL-6 trans-signalling pathway offers potential for safer, more precise therapies, as it accounts for distinct roles in disease and homeostasis.

• Why it matters: Current IL-6 therapies risk disrupting essential functions, leading to safety concerns, highlighting the need for approaches that distinguish between signalling modes to improve treatment specificity.
• What they did: The authors review the molecular mechanisms of IL-6 signalling, including classic and trans-signalling, and compare global versus selective therapeutic strategies, emphasizing the regulation by sgp130 and ADAM17.
• The result: Understanding these differences enables the development of targeted drugs that modulate IL-6 responses more precisely, potentially improving efficacy and safety in treating autoimmune and inflammatory diseases.